Dow Up0.08% Nasdaq Down0.30%

Novo Nordisk A/S (NVO)

-NYSE
48.41 0.62(1.26%) Sep 19, 4:02PM EDT
ProfileGet Profile for:
Novo Nordisk A/S
Novo All
Bagsvaerd, 2880
Denmark - Map
Phone: 45 44 44 88 88
Fax: 45 44 49 05 55
Website: http://www.novonordisk.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:40,226

Business Summary 

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation. The company sells its products primarily in North America, China, Japan, Algeria, Argentina, Australia, Brazil, India, Turkey, and European countries through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Novo Nordisk A/S

Key Executives 
 PayExercised
Mr. Lars Rebien S , 60
Chief Exec. Officer
3.35M0.00
Mr. K Schultz , 53
Pres and Chief Operating Officer
2.03M0.00
Mr. Jesper Brandgaard MSc, 51
Chief Financial Officer, Exec. VP, Chairman - Novo Nordisk Engineering A/S and Chairman of the Board - Novo Nordisk IT A/S
1.80M0.00
Dr. Mads Krogsgaard Thomsen Ph.D., 54
Chief Science Officer and Exec. VP
1.80M0.00
Mr. Lars Fruergaard J , 48
Chief Information Officer and Exec. VP
1.25M0.00
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.